March 18, 2019
FDA: Hospira recalls 8.4% Sodium Bicarbonate Injection
Editor's Note
The Food and Drug Administration (FDA) on March 15 announced the recall by Hospira, Inc (a Pfizer company) of three lots of its 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL).
The recall was initiated because of the presence of particulate matter, confirmed as glass.
The lots and expiration dates are:
- 79-238-EV (Exp July 1, 2019)
- 79-240-EV (Exp July 1, 2019)
- 80-088-EV (Exp August 1, 2019).
The affected lots were distributed from August 2017 to September 2017.
Free Daily News
- Study finds workforce readiness gap in new nurses
- Joint replacement manufacturer recalls products after FDA packaging warning
- Gene-edited pig kidney, heart pump combined in transplant surgery milestone
- Catheter sterility concerns prompt Class 1 FDA recall for surgery trays
- Large amounts of personal data possibly stolen in Change Healthcare cyberattack
- AI model helps predict patient decline, drive collaborative care
- One patient’s recovery highlights benefits of outpatient endoscopic spine surgery
- Getting ready for the OAS CAHPS Survey 2025 requirement
- Contribute to perioperative education with the 2024 OR Manager Salary/Career Survey
- Supply chain stability improves, but threats remain
© Access Intelligence, LLC. All rights reserved. | Privacy Policy | Diversity, Equity, Inclusion & Belonging